AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14980363 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment and case management for 6 months (treatment group)
Number of subjects: 188
Study 14980363 — intervention group
Group type: COMPARATOR
Intervention: Control group provided a list of available services
Number of subjects: 188
Study 11751188 — intervention group
Group type: EXPERIMENTAL
Intervention: SpiroGame
Number of subjects: 102
Study 11751188 — intervention group
Group type: COMPARATOR
Intervention: Candle-blowing
Number of subjects: 102
Study 9358379 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer incentives (reward for returning signed forms)
Number of subjects: 0
Study 9358379 — intervention group
Group type: COMPARATOR
Intervention: No peer incentives (control group)
Number of subjects: 0
Study 9358379 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer incentives
Number of subjects: 0
Study 9358379 — intervention group
Group type: EXPERIMENTAL
Intervention: Desire to be protected
Number of subjects: 0
Study 9358379 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual rewards
Number of subjects: 0
Study 8406323 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg/day for 1 month
Number of subjects: 32
Study 8406323 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 3543231 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg q.d.)
Number of subjects: 382
Study 3543231 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg b.i.d.)
Number of subjects: 382
Study 3543231 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg q.d.) plus hydrochlorothiazide (25 mg)
Number of subjects: 382
Study 3543231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 382
Study 29985080 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX + adalimumab (n = 89)
Number of subjects: 180
Study 29985080 — intervention group
Group type: COMPARATOR
Intervention: MTX + placebo (n = 91)
Number of subjects: 180
Study 28296012 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure-specific consent form
Number of subjects: 0
Study 28296012 — intervention group
Group type: COMPARATOR
Intervention: Standard consent form
Number of subjects: 0
Study 25794984 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 0
Study 25794984 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24295237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Treatment (CBT)
Number of subjects: 60
Study 24295237 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 60
Study 24295237 — intervention group
Group type: EXPERIMENTAL
Intervention: PDSS-C scores
Number of subjects: 60
Study 24295237 — intervention group
Group type: EXPERIMENTAL
Intervention: PDSS-C change scores
Number of subjects: 60
Study 23250176 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine solution (0.12%)
Number of subjects: 120
Study 23250176 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave sterilization (7 minutes)
Number of subjects: 120
Study 23250176 — intervention group
Group type: COMPARATOR
Intervention: Sterile tap water
Number of subjects: 120
Study 20002116 — intervention group
Group type: EXPERIMENTAL
Intervention: Home stimulation programme updated every 3 months, including activities to promote motor, cognitive, and speech and language development.
Number of subjects: 122
Study 20002116 — intervention group
Group type: COMPARATOR
Intervention: No developmental intervention (comparison group).
Number of subjects: 122
Study 18777846 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15727504 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oral methylphenidate
Number of subjects: 6
Study 15727504 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 6
Study 15727504 — intervention group
Group type: EXPERIMENTAL
Intervention: triazolam
Number of subjects: 6
Study 15727504 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 6
Study 12576803 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 0
Study 12576803 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 10578803 — intervention group
Group type: COMPARATOR
Intervention: Optimal breastfeeding technique alone
Number of subjects: 84
Study 10578803 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mupiricin
Number of subjects: 84
Study 10578803 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical fusidic acid
Number of subjects: 84
Study 10578803 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antibiotics
Number of subjects: 84
Study 10578803 — intervention group
Group type: COMPARATOR
Intervention: Not treated with systemic antibiotics
Number of subjects: 84
Study 10578803 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated with systemic antibiotics
Number of subjects: 84
Study 8916978 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist therapy with add-back hormone replacement therapy (HRT)
Number of subjects: 0
Study 8916978 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex (goserelin acetate) with add-back HRT
Number of subjects: 0
Study 8417553 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 89
Study 8417553 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 89
Study 3510196 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam with propranolol
Number of subjects: 27
Study 3510196 — intervention group
Group type: COMPARATOR
Intervention: Placebo with propranolol
Number of subjects: 27
Study 29378227 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-aged trained (MAT)
Number of subjects: 40
Study 29378227 — intervention group
Group type: EXPERIMENTAL
Intervention: Young trained (YT)
Number of subjects: 40
Study 29378227 — intervention group
Group type: COMPARATOR
Intervention: Young groups
Number of subjects: 40
Study 29378227 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 40
Study 26831299 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of GLP-1 at 0.6 pmol kg(‐1) min(‐1) (1 ml/min)
Number of subjects: 12
Study 26831299 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile infusion of GLP-1 with a bolus of 3.6 pmol/kg every 6 min (placebo at 1 ml/min)
Number of subjects: 12
Study 26831299 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion (1 ml/min)
Number of subjects: 12
Study 23715004 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 0
Study 23715004 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal steroid (INS)
Number of subjects: 0
Study 21334899 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculo-motor exercises and gaze stability exercises for three weeks
Number of subjects: 41
Study 21334899 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study 19808377 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma urocortin 1 levels in patients with heart failure
Number of subjects: 299
Study 19808377 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma urocortin 1 levels
Number of subjects: 299
Study 17803204 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 44
Study 17803204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 44
Study 15468186 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg twice daily)
Number of subjects: 106
Study 15468186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 11576162 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (TR)
Number of subjects: 21
Study 11576162 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 21
Study 9403533 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefepime plus metronidazole (n=164)
Number of subjects: 323
Study 9403533 — intervention group
Group type: COMPARATOR
Intervention: Imipenem-cilastatin (n=159)
Number of subjects: 323
Study 8273766 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 2 mg/d sublingually
Number of subjects: 5
Study 8273766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 2949024 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin (400 mg loading dose followed by 200 mg/day)
Number of subjects: 0
Study 2949024 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin (8 g/day)
Number of subjects: 0
Study 29444664 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week knitting program including bi-weekly 20-min knitting sessions at a senior's club and 20-min home daily knitting sessions for five weekdays.
Number of subjects: 0
Study 29444664 — intervention group
Group type: COMPARATOR
Intervention: Educational pamphlet on osteoarthritis (OA) designed by the Arthritis Society.
Number of subjects: 0
Study 26105060 — intervention group
Group type: EXPERIMENTAL
Intervention: Empowerment theory-based education program
Number of subjects: 86
Study 26105060 — intervention group
Group type: COMPARATOR
Intervention: Standard education program
Number of subjects: 86
Study 24469621 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency endovascular repair (EVAR)
Number of subjects: 147
Study 24469621 — intervention group
Group type: COMPARATOR
Intervention: Open surgical repair
Number of subjects: 147
Study 22563440 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole 5 mg/kg/d for 24 weeks
Number of subjects: 35
Study 22563440 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 weeks
Number of subjects: 35
Study 20881073 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine-supplemented perioperative enteral nutrition (n = 17)
Number of subjects: 32
Study 20881073 — intervention group
Group type: COMPARATOR
Intervention: Standard perioperative enteral nutrition (n = 15)
Number of subjects: 32
Study 18213374 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria vaccine FMP2.1/AS02A (25 microg/0.25 mL or 50 microg/0.5 mL)
Number of subjects: 60
Study 18213374 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria vaccine FMP2.1/AS02A (half-dose)
Number of subjects: 60
Study 18213374 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria vaccine FMP2.1/AS02A (full-dose)
Number of subjects: 60
Study 18213374 — intervention group
Group type: COMPARATOR
Intervention: Rabies vaccine (RabAvert)
Number of subjects: 60
Study 15734497 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt of Continuous Flow (SCF)
Number of subjects: 307
Study 15734497 — intervention group
Group type: COMPARATOR
Intervention: Conventional Valvular Shunt
Number of subjects: 307
Study 12671339 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy
Number of subjects: 0
Study 10375153 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity assertive community treatment programs
Number of subjects: 87
Study 10375153 — intervention group
Group type: COMPARATOR
Intervention: Low-fidelity assertive community treatment programs
Number of subjects: 87
Study 8889481 — intervention group
Group type: COMPARATOR
Intervention: CC (cool environment)
Number of subjects: 12
Study 8889481 — intervention group
Group type: EXPERIMENTAL
Intervention: CH (hot, humid environment)
Number of subjects: 12
Study 8889481 — intervention group
Group type: EXPERIMENTAL
Intervention: HH (hot, humid environment)
Number of subjects: 12
Study 1872343 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (450 mg, orally four times daily for 14 days)
Number of subjects: 126
Study 1872343 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (333 mg, orally four times daily for 14 days)
Number of subjects: 126
Study 1872343 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally four times daily for 14 days)
Number of subjects: 126
Study 1872343 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (333 mg)
Number of subjects: 126
Study 1872343 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (450 mg)
Number of subjects: 126
Study 1872343 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliance
Number of subjects: 126
Study 7072831 — intervention group
Group type: EXPERIMENTAL
Intervention: Polycon contact lenses
Number of subjects: 8
Study 7072831 — intervention group
Group type: COMPARATOR
Intervention: PMMA contact lenses
Number of subjects: 8
Study 31350778 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-coordinated integrated care model
Number of subjects: 392
Study 31350778 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 392
Study 28511243 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotional arousal (measured via vocal fundamental frequency, f0) during social support interactions
Number of subjects: 44
Study 25782136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition mnemonic skill training (method of loci) for three 1-hour sessions
Number of subjects: 141
Study 25782136 — intervention group
Group type: COMPARATOR
Intervention: No cognitive training (Control)
Number of subjects: 141
Study 25782136 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition mnemonic skill training
Number of subjects: 141
Study 24166407 — intervention group
Group type: EXPERIMENTAL
Intervention: Video gaming training with a platformer game for 2 months, at least 30 minutes per day
Number of subjects: 0
Study 24166407 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 21921817 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CM) 20 g·d⁻¹ for 7 days
Number of subjects: 22
Study 21921817 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin) 20 g·d⁻¹ for 7 days
Number of subjects: 22
Study 19429735 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-recorded NRS
Number of subjects: 528
Study 19429735 — intervention group
Group type: EXPERIMENTAL
Intervention: Research-recorded NRS
Number of subjects: 528
Study 17124389 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day for 3 months
Number of subjects: 83
Study 17124389 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 83
Study 15223991 — intervention group
Group type: EXPERIMENTAL
Intervention: MIDD1
Number of subjects: 77
Study 15223991 — intervention group
Group type: COMPARATOR
Intervention: MIDD1/T1D
Number of subjects: 77
Study 15223991 — intervention group
Group type: COMPARATOR
Intervention: MIDD2/T2D
Number of subjects: 77
Study 12470528 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 5 embryo transfer
Number of subjects: 0
Study 12470528 — intervention group
Group type: COMPARATOR
Intervention: Day 3 embryo transfer
Number of subjects: 0
Study 9464734 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg nitroglycerin
Number of subjects: 97
Study 9464734 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg nitroglycerin
Number of subjects: 97
Study 9464734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 7637681 — intervention group
Group type: EXPERIMENTAL
Intervention: Natamycin (suspension, lozenges)
Number of subjects: 46
Study 7637681 — intervention group
Group type: EXPERIMENTAL
Intervention: Nystatin (suspension)
Number of subjects: 46
Study 7637681 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (suspension, lozenges)
Number of subjects: 46
Study 7637681 — intervention group
Group type: EXPERIMENTAL
Intervention: Candida serology (indirect haemagglutination, indirect immunofluorescence and immunodiffusion precipitation)
Number of subjects: 46
Study 7637681 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical picture, culture and serology
Number of subjects: 46
Study 2236482 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural methods
Number of subjects: 0
Study 2236482 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 355881 — intervention group
Group type: COMPARATOR
Intervention: Therapies labeled as 'no different from control'
Number of subjects: 71
Study 355881 — intervention group
Group type: COMPARATOR
Intervention: Estimates of 90% confidence intervals for true improvement
Number of subjects: 71
Study 31927774 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg and Tamsulosin 0.4 mg (DUT-TAM FDC)
Number of subjects: 489
Study 31927774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 489
Study 30952918 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic treatment for 12 weeks
Number of subjects: 68
Study 30952918 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 12 weeks
Number of subjects: 68
Study 28180234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecarfarin (SAD)
Number of subjects: 137
Study 28180234 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecarfarin (MAD)
Number of subjects: 137
Study 28180234 — intervention group
Group type: COMPARATOR
Intervention: Tecarfarin (vs Warfarin)
Number of subjects: 137
Study 26643000 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-Eluting Stent
Number of subjects: 279
Study 26643000 — intervention group
Group type: COMPARATOR
Intervention: Conventional Stent
Number of subjects: 279
Study 23770335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix(®) administered intradermally
Number of subjects: 40
Study 23770335 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardasil(®) administered intradermally
Number of subjects: 40
Study 23770335 — intervention group
Group type: COMPARATOR
Intervention: Cervarix(®) administered intramuscularly
Number of subjects: 40
Study 23770335 — intervention group
Group type: COMPARATOR
Intervention: Gardasil(®) administered intramuscularly
Number of subjects: 40
Study 21527006 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil
Number of subjects: 540
Study 21527006 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 540
Study 18812277 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES (mW 130 kDa)
Number of subjects: 45
Study 18812277 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES (mW 200 kDa)
Number of subjects: 45
Study 18812277 — intervention group
Group type: COMPARATOR
Intervention: 4% HA (MW 69 kDa)
Number of subjects: 45
Study 16942451 — intervention group
Group type: EXPERIMENTAL
Intervention: Education by opinion leaders about whiplash guidelines
Number of subjects: 103
Study 16942451 — intervention group
Group type: COMPARATOR
Intervention: Dissemination of guidelines mailed to physiotherapists
Number of subjects: 103
Study 14563466 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud pack treatment (30 mm thickness)
Number of subjects: 20
Study 14563466 — intervention group
Group type: EXPERIMENTAL
Intervention: Mud pack treatment (15 mm thickness)
Number of subjects: 20
Study 10744097 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz transcranial magnetic stimulation of left temporoparietal cortex
Number of subjects: 12
Study 10744097 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 12
Study 8602588 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine
Number of subjects: 24
Study 8602588 — intervention group
Group type: COMPARATOR
Intervention: White wine
Number of subjects: 24
Study 1349493 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol 10 mg
Number of subjects: 8
Study 1349493 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol 30 mg
Number of subjects: 8
Study 1349493 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol 60 mg
Number of subjects: 8
Study 1349493 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol 40 mg
Number of subjects: 8
Study 1349493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg
Number of subjects: 8
Study 1349493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1349493 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 8
Study 4078356 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine
Number of subjects: 18
Study 4078356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone
Number of subjects: 18
Study 4078356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone with Clofazimine
Number of subjects: 18
Study 4078356 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin alone (Control)
Number of subjects: 18
Study 31805967 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy
Number of subjects: 336
Study 31805967 — intervention group
Group type: COMPARATOR
Intervention: No corticosteroid therapy
Number of subjects: 336
Study 31805967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisoltotal/CRP ratio > 3
Number of subjects: 336
Study 31805967 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisoltotal/CRP ratio < 3
Number of subjects: 336
Study 30188739 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 39
Study 30188739 — intervention group
Group type: COMPARATOR
Intervention: Waiting-List (WL)
Number of subjects: 39
Study 26669629 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 336
Study 26669629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 336
Study 24776962 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐T4 plus 100 μg/day of oral iodine
Number of subjects: 51
Study 24776962 — intervention group
Group type: COMPARATOR
Intervention: L‐T4
Number of subjects: 51
Study 22976782 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus 0.5% clarithromycin (CLM)
Number of subjects: 63
Study 22976782 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) plus placebo gel
Number of subjects: 63
Study 19578138 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive CD with verbal feedback
Number of subjects: 96
Study 19578138 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive CD with additional practice with parents
Number of subjects: 96
Study 19578138 — intervention group
Group type: COMPARATOR
Intervention: Interactive CD without verbal feedback
Number of subjects: 96
Study 19578138 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive CD
Number of subjects: 96
Study 17335321 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin (3‐12 mg/night; N = 20)
Number of subjects: 40
Study 17335321 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 20)
Number of subjects: 40